Can-Fite BioPharma (NYSE:CANF) Coverage Initiated by Analysts at StockNews.com

Posted by Teresa Graham on May 9th, 2024

StockNews.com started coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note published on Wednesday. The firm issued a hold rating on the stock.

Can-Fite BioPharma Stock Up 7.9 %

CANF opened at $2.18 on Wednesday. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $3.33. The business has a 50 day moving average of $2.14 and a 200-day moving average of $2.10. The stock has a market cap of $7.72 million, a price-to-earnings ratio of -1.13 and a beta of 1.58.

Can-Fite BioPharma (NYSE:CANF – Get Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04). The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.20 million. Can-Fite BioPharma had a negative return on equity of 113.75% and a negative net margin of 1,027.46%. As a group, analysts expect that Can-Fite BioPharma will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently bought a new stake in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned about 0.57% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. 21.00% of the stock is owned by institutional investors.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.